scispace - formally typeset
Open Access

Prevalence of agerelated macular degeneration in the united states

TLDR
Age-related macular degeneration was far more prevalent among white than among black persons, and the number of persons having AMD will increase by 50% to 2.95 million in 2020.
Abstract
To estimate the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender. Summary prevalence estimates of drusen 125 microm or larger, neovascular AMD, and geographic atrophy were prepared separately for black and white persons in 5-year age intervals starting at 40 years. The estimated rates were based on a meta-analysis of recent population-based studies in the United States, Australia, and Europe. These rates were applied to 2000 US Census data and to projected US population figures for 2020 to estimate the number of the US population with drusen and AMD. The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy. More than 7 million individuals had drusen measuring 125 microm or larger and were, therefore, at substantial risk of developing AMD. Owing to the rapidly aging population, the number of persons having AMD will increase by 50% to 2.95 million in 2020. Age-related macular degeneration was far more prevalent among white than among black persons. Age-related macular degeneration affects more than 1.75 million individuals in the United States. Owing to the rapid aging of the US population, this number will increase to almost 3 million by 2020

read more

Citations
More filters
Journal ArticleDOI

Ranibizumab for Neovascular Age-Related Macular Degeneration

TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal ArticleDOI

Complement Factor H Polymorphism in Age-Related Macular Degeneration

TL;DR: A genome-wide screen for polymorphisms associated with age-related macular degeneration revealed a polymorphism in linkage disequilibrium with the risk allele representing a tyrosine-histidine change at amino acid 402 in the complement factor H gene.
Journal ArticleDOI

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

TL;DR: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.
Journal ArticleDOI

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.

TL;DR: In this article, the authors did a systematic literature review to identify all population-based studies of age-related macular degeneration published before May, 2013, using retinal photographs and standardised grading classifications.
References
More filters
Journal ArticleDOI

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.

TL;DR: To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with verteporfin (Visudyne) in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration (AMD).
Journal ArticleDOI

An international classification and grading system for age-related maculopathy and age-related macular degeneration

TL;DR: A common detection and classification system is needed for epidemiologic studies of age-related maculopathy (ARM) and such a grading scheme for ARM is described in this paper.
Journal ArticleDOI

Prevalence of Age-related Maculopathy in Australia: The Blue Mountains Eye Study

TL;DR: Detailed prevalence rates for most components of ARM in an Australian population are provided and reinforce the Beaver Dam Eye Study findings for the relative age-specific frequency of age-related macular degeneration components.
Journal ArticleDOI

Racial differences in the cause-specific prevalence of blindness in east Baltimore

TL;DR: The pattern of blindness in urban Baltimore appears to be different among blacks and whites, with Whites are far more likely to have age-related macular degeneration, and blacks to have primary open-angle glaucoma.
Journal ArticleDOI

Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration.

TL;DR: Depressive disorder is a significant problem for the elderly afflicted with advanced macular degeneration and treatment strategies that teach patients to cope with vision loss should be developed and evaluated.
Related Papers (5)

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8